Literature DB >> 11267012

Primate skin allotransplantation with anti-CD154 monotherapy.

E A Elster1, H Xu, D K Tadaki, L C Burkly, J D Berning, R E Baumgartner, F Cruzata, N B Patterson, D M Harlan, A D Kirk.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11267012     DOI： 10.1016/s0041-1345(00)02197-7

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

1.  Skin allograft maintenance in a new synchimeric model system of tolerance.

Authors:  N N Iwakoshi; T G Markees; N Turgeon; T Thornley; A Cuthbert; J Leif; N E Phillips; J P Mordes; D L Greiner; A A Rossini
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

Review 2.  Induction of transplantation tolerance in non-human primate preclinical models.

Authors:  Douglas A Hale; Kiran Dhanireddy; David Bruno; Allan D Kirk
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 3.  Primate models in organ transplantation.

Authors:  Douglas J Anderson; Allan D Kirk
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

4.  Adipose-derived stromal cells promote allograft tolerance induction.

Authors:  Thomas A Davis; Khairul Anam; Yelena Lazdun; Jeffrey M Gimble; Eric A Elster
Journal:  Stem Cells Transl Med       Date:  2014-11-19       Impact factor: 6.940

5.  IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice.

Authors:  Jeong-hoon Lee; Jongwon Ha; Shi-hwa Kim; Sang Joon Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

6.  Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation.

Authors:  A H Charafeddine; E J Kim; D M Maynard; H Yi; T A Weaver; M Gunay-Aygun; M Russell; W A Gahl; A D Kirk
Journal:  Am J Transplant       Date:  2012-09-04       Impact factor: 8.086
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.